Participated · Series D · Feb 2022

CelLink manufactures electrically and thermally conductive flexible circuits intended to redefine automotive electrical distribution systems to make vehicles lighter, less expensive, and cleaner in both manufacturing and daily use. Founded in 2012 by Kevin Coakley and Malcolm Brown, the company is headquartered in San Carlos, CA, with a sales and engineering facility in Novi, MI. Its products have been in automotive mass production since 2019 and are on the road in hundreds of thousands of electric vehicles today. The company closed a $250M Series D to fund growth. Proceeds will finance construction of a 300,000 sq. ft. manufacturing facility in Georgetown, Texas, expand engineering teams at its San Carlos HQ and Novi facility, and establish a European-based team to service international customers. CelLink plans to expand the application of its technology beyond passenger automotive into commercial vehicles, aerospace, off-highway, agriculture, military, marine, and other industrial markets.

Led · Series B · Feb 2021

Softwear Automation builds the SEWBOT® platform, a fully autonomous sewing solution that combines advanced robotics, machine vision, and AI/ML to automate sewn-goods production. The company targets the $1.1 trillion sewn products industry with a focus on localized, scalable, and sustainable manufacturing. Its SEWBOT® worklines aim to reduce waste, shorten cycle times, and improve cost efficiency while enabling on-demand and closer-to-consumer production. Softwear is progressing toward commercialization of its automated worklines and is expanding its R&D capabilities to support broader product categories. The company plans to scale its production footprint and enter new geographies to meet growing global demand. Softwear positions its technology as a tool to enable more circular, demand-driven apparel production and to improve supply-chain transparency. Softwear Automation develops sewing robots, called SewBots, and uses robotics and artificial intelligence to automate the manufacturing of sewn goods such as clothing, towels and footwear. The company says its SewBots make it cost efficient to manufacture textiles anywhere in the world, and according to its website it was not taking orders for the robots until July 2022. Softwear spun out of Georgia Tech after seven years of research, supported by grants from The Walmart Foundation, DARPA and the Georgia Research Alliance. Founded in 2012 and based in Atlanta, the startup expanded into a 50,000-square-foot industrial space in 2017 and that year raised $4.5 million and doubled its workforce. Financially, the company began raising its latest round in 2019 and reported closing about $12 million that year; it subsequently reported closing an $18.1 million Series B in a Feb. 1 SEC filing. SoftWear Automation develops robotic sewing worklines branded as Sewbots™ for apparel, footwear and home goods. The company uses patented computer vision systems that track fabric and exact needle placement to within half a millimeter. Led by Chairman and CEO Palaniswamy “Raj” Rajan, SoftWear positions its technology to allow manufacturers to move supply chains closer to customers and lower production costs. The company received $4.5M in financing to accelerate its product development. It intends to use the funds to speed development of fully automated sewn-good worklines specifically for apparel production in the United States and to add 20 employees. The company is based in Atlanta. SoftWear Automation is an Atlanta, Ga.-based developer of robotic sewing technologies for the garment industry. The company provides machine vision, robotics, and computing technologies and products for the apparel manufacturing and sewn products industries. Its core product set is designed to automate garment production lines. SoftWear completed a $3M Series A round of financing. The financing was made by VC firm CTW Venture Partners. K.P. Reddy, a CTW partner, has joined SoftWear as CEO.

Participated · Series A · Sep 2017

Silk Therapeutics develops clean, EWG VERIFIED skincare collections built around pure, liquid silk as the core active ingredient. After receiving five patent approvals in 2016, the company built a natural chemistry platform to produce liquid silk at mass scale. Leadership under CEO Greg Altman and COO Rebecca Lacouture has extended the technology beyond skincare: testing revealed use cases in fabrics where liquid silk infused into the surface layer offers benefits for performance apparel. The company is focused on expanding its development efforts and commercial applications of the liquid silk platform. Financially, Silk Therapeutics recently closed an $11M Series A3 financing to support those development plans. Silk Therapeutics is a Boston, MA–based company that provides silk protein solutions for human health and wellness. The company has patented natural silk protein technology for use in consumer goods and medical applications and offers a skincare product line designed to renew, fortify and nurture the skin. Led by CEO Dr. Greg Altman and COO Dr. Rebecca Horan, Silk will use the new capital to expand its skincare product line and begin exploring additional consumer markets. The company closed a $6M Series A2 financing round to support those efforts. The round was led by existing investor The Kraft Group and included participation from Lear Corporation, Highland Consumer Partners, Sheri and Roy P. Disney, Richard Sackler, MD (with Summer Road, LLC), Erin Donohue and Ron Bresler (BML Group), and Altman Health Investments. With this A2, Silk has now raised a total of $10.25M in Series A funding. Silk Therapeutics develops silk protein–based solutions focused on skin health and wellness. The company is preparing to launch a sensitive skincare treatment line in the second half of the year aimed at people with sensitive skin, eczema, and oncology patients undergoing chemotherapy and radiation. Products are designed to heal, soothe and restore damaged and inflamed skin. Leadership includes Gregory Altman, PhD (CEO and co‑Founder), and Rebecca Horan, PhD (COO). Silk Therapeutics recently closed a $3M Series A1 financing to support its product plans and operations. The company is based in Boston, MA.